Paratus Clinical   Report issue

For profit Phase 2
Founded: North Sydney Australia (2013)

Organization Overview

First Clinical Trial
2019
NCT03880474
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Paratus Clinical | Paratus Clinical Pty Ltd

Active Ingredients

Drugs in Phase 2 Trials (4)

liraglutide (victoza) (1 trial)

matrix m1 (1 trial)

mva-np (1 trial)

xw003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4